18 F-FDG-PET/CT imaging in diagnostic workup of pediatric precursor B-cell lymphoblastic lymphoma

Pediatr Blood Cancer. 2023 Nov;70(11):e30642. doi: 10.1002/pbc.30642. Epub 2023 Aug 28.

Abstract

18 F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) imaging is currently not used in standard diagnostics for B-cell precursor lymphoblastic lymphoma (BCP-LBL), and it is unknown whether PET/CT imaging would lead to agreement between detection of lesions with the gold standard imaging methods. Therefore, we performed a retrospective cohort study in which we included 32 pediatric BCP-LBL patients and determined localizations by reviewing local imaging reports. There was a disagreement between protocol-based imaging and PET/CT in 59% of the patients, and the discrepancies mostly comprise of additional lesions detected with PET/CT, typically in lymph node and bone or the absence of bone marrow involvement with PET/CT. If PET/CT was leading in determining definite stage of disease, this would lead to a different stage and therapy branch in 31% and 28% of the patients, respectively.

Keywords: 18F-FDG-PET/CT; B-cell; PET/CT; diagnostics; imaging; lymphoblastic lymphoma; non-Hodgkin lymphoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Diagnostic Imaging
  • Fluorodeoxyglucose F18*
  • Humans
  • Positron Emission Tomography Computed Tomography
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / diagnostic imaging
  • Retrospective Studies

Substances

  • Fluorodeoxyglucose F18